ストックスクリーナーアプリを入手
2.162
0.37%
-0.008
アフターアワーズ：
2.12
-0.042
-1.94%
前日終値:
$2.17
開ける：
$2.22
24時間の取引高:
28,698
Relative Volume:
0.02
時価総額：
$4.63M
収益：
$743.00K
当期純損益:
$-7.63M
株価収益率:
-0.1737
EPS:
-12.4498
ネットキャッシュフロー:
-
1週間 パフォーマンス:
-3.48%
1か月 パフォーマンス:
-34.88%
6か月 パフォーマンス:
-33.07%
1年 パフォーマンス:
-82.28%
1日の値動き範囲:
$2.15
$2.22
1週間の範囲:
$2.15
$2.28
52週間の値動き範囲:
$2.15
$12.80
Can-Fite Biopharma Ltd ADR Stock (CANF) Company Profile
名前
Can-Fite Biopharma Ltd ADR
セクター
電話
972 3 924 1114
住所
10 Bareket Street, Kiryat Matalon PO Box 7537, Petah-Tikva
Compare CANF vs VRTX, REGN, MRNA, ARGX, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
CANF
Can-Fite Biopharma Ltd ADR
|
2.162 | 4.63M | 743.00K | -7.63M | 0 | -12.45 |
VRTX
Vertex Pharmaceuticals Inc
|
526.19 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
788.04 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
198.88 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
959.49 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
204.97 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Can-Fite Biopharma Ltd ADR Stock (CANF) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2017-08-11 | 開始されました | Maxim Group | Buy |
| 2016-10-19 | 再開されました | ROTH Capital | Buy |
| 2016-08-29 | 再開されました | Rodman & Renshaw | Buy |
| 2015-11-30 | 繰り返されました | H.C. Wainwright | Buy |
| 2015-03-31 | 繰り返されました | H.C. Wainwright | Buy |
| 2015-03-30 | ダウングレード | ROTH Capital | Buy → Neutral |
| 2014-12-29 | 繰り返されました | ROTH Capital | Buy |
| 2014-11-18 | 開始されました | H.C. Wainwright | Buy |
すべてを表示
Can-Fite Biopharma Ltd ADR (CANF) 最新ニュース
CANF Stock Price, Quote & Chart - ChartMill
Warrants on 7.6M CANF shares highlight dilution risk - Stock Titan
CANFCan-Fite Biopharma Ltd ADR Short Interest - Finviz
Can-Fite BioPharma to Raise Approximately $4 Million Through Warrant Exercise (AMEX: CANF) - Kalkine Media
Which stocks are gapping on Wednesday? - ChartMill
Discover the top movers in Wednesday's pre-market session. - ChartMill
Can-Fite Highlights Advanced FDA and EMA Regulatory Status of its Phase III Drug Candidates - Sahm
Can-Fite Positive Phase 2a Pancreatic Cancer Study Data Accepted for Presentation at ESMO Congress 2026, One of the World's Premier Scientific Meetings in Oncology - GlobeNewswire Inc.
Can-Fite Secures Australian Patent Allowance Supporting Namodenoson Development and Marketing in Liver and Pancreatic Cancer - Sahm
symbol__ Stock Quote Price and Forecast - CNN
Why is Can-Fite BioPharma stock climbing today? - Investing.com
Can-Fite Highlights Survival Outcomes In Pancreatic Cancer Patients - Sahm
H.C. Wainwright raises Can-Fite BioPharma price target to $8 on trial data - Investing.com
Wednesday's session: gap up and gap down stocks - ChartMill
Can Fite Biopharma stock surges 65% on pancreatic cancer data By Investing.com - Investing.com Nigeria
Can Fite Biopharma stock surges 65% on pancreatic cancer data - Investing.com
What's going on in today's pre-market session - ChartMill
Can-Fite BioPharma Ltd. Sponsored ADR Financial Disclosures & SEC Filings - TradingView
Can-Fite BioPharma Ltd. Sponsored ADR Actuals & Estimates (AMEX:CANF) - TradingView
12 Health Care Stocks Moving In Friday's Pre-Market Session - Sahm
Can-Fite BioPharma (NYSEAMERICAN:CANF) jumps after Japan patent update - TechStock²
Can Fite Biopharma stock jumps on Japan patent for obesity drug - Investing.com South Africa
Top movers in Friday's pre-market session - ChartMill
Can-Fite Publishes Peer-Reviewed Scientific Article Demonstrating the Broad Therapeutic Potential of Piclidenoson and Namodenoson - Sahm
Form 6K Can-Fite BioPharma Ltd. For: 22 June By Investing.com - Investing.com South Africa
Can-Fite to Present Late-Stage Clinical Pipeline and Licensing Opportunities at BIO International Convention 2026 - Sahm
CANF Technical Analysis | Trend, Signals & Chart Patterns | CAN FITE BIOPHARMA LTD-ADR (NYSEARCA:CANF) - ChartMill
CANF Stock Chart | CAN FITE BIOPHARMA LTD-ADR (NYSEARCA:CANF) - ChartMill
Scientific Publication of Can-Fite and Vetbiolix Validates Piclidenoson’s Potential in the Multi-Billion Dollar Canine Osteoarthritis Market - Sahm
Can Fite Biopharma stock rises on osteoarthritis study publication - Investing.com
D. Boral Capital upgrades Can-Fite BioPharma stock rating on oncology pipeline progress - Investing.com
What Can-Fite Bio (CANF) is doing that could pay off big later (Rallies Strongly) 2026-05-08Long Term Investing - newser.com
Can-Fite Reports Positive Phase 2a Data with Namodenoson in Pancreatic Cancer; 35% of Patients Remain on Therapy, Including One Beyond 16 Months - ChartMill
CANF Ownership | CAN FITE BIOPHARMA LTD-ADR (NYSEARCA:CANF) - ChartMill
Can Fite Biopharma Ltd ADR (CANF) - Minichart
Can-Fite’s Partner Vetbiolix Completes Enrollment in Phase 2 Osteoarthritis Study in Dogs Treated with Piclidenoson; Data Expected in Q3 2026 - ChartMill
Can-Fite Reports 2025 Financial Results and Ongoing Clinical Progress Highlighting Positive Data in Phase 2a Pancreatic cancer and 9 Years Cancer-Free Survival in Liver Cancer Patient - ChartMill
Can-Fite reports 2025 loss, raises $4.3 million in March - Investing.com
Can-Fite Expands Namodenoson anti-Obesity Franchise with Israeli Patent Allowance - Sahm
12 Health Care Stocks Moving In Wednesday's After-Market Session - Sahm
CANF Stock Soars 20% on Positive Mid-Stage Pancreatic Cancer Data - Finviz
Can-Fite BioPharma raises $4M through warrant exercise - Investing.com
Can Fite Biopharma stock rises after patient success with liver treatment - Investing.com
Curious about the most active stocks on Friday? - ChartMill
These stocks that are showing activity before the opening bell on Wednesday. - ChartMill
Can-Fite Announces Reverse Split of its Ordinary Shares and ADS Ratio Change - Yahoo Finance
Can Fite Biopharma Ltd ADR (NYSE: CANF) Share Price, CANF Stock News, CANF Share Price & Updates - Kalkine
Let's uncover which stocks are experiencing notable gaps during today's session. - ChartMill
Top movers in Monday's session - ChartMill
Can-Fite’s Surging Stock: Is It Time to Act? - timothysykes.com
Which stocks are gapping on Tuesday? - ChartMill
Can-Fite Biopharma Ltd ADR (CANF) 財務データ
収益
当期純利益
現金流量
EPS
3.06%
2.55%
大文字化:
|
ボリューム (24 時間):